Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory Mycobacterium avium complex lung disease.

Marraset al. report a low number needed to treat and high number needed to harm supporting addition of amikacin liposome inhalation suspension to guideline-based treatments in patients with treatment-refractory Mycobacterium avium complex lung disease https://bit.ly/3tPFW7D.